Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 6/20 | 0.46 |
| ▸ | MAOA | P21397 | 5/20 | 0.45 |
| ▸ | MAOB | P27338 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | CALML3 | P27482 | 1/20 | 0.43 |
| ▸ | SDHA | P31040 | 1/20 | 0.43 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6401959 | 0.93 | F10 (0.45) | F10MAOAMAOBLMNAPTGS1 | |
| SCHEMBL6401956 | 0.93 | F10 (0.45) | F10MAOAMAOBLMNAPTGS1 | |
| SCHEMBL7119633 | 0.90 | MAOA (0.48) | F10MAOAMAOBLMNAPTGS1 | |
| SCHEMBL8139877 | 0.85 | MAOA (0.46) | F10MAOAMAOBLMNAPTGS1 | |
| SCHEMBL7821646 | 0.84 | MAOA (0.48) | F10MAOAMAOBLMNAPTGS1 | |
| SCHEMBL8135586 | 0.82 | F10 (0.41) | F10MAOAMAOBLMNAPTGS1 | |
| SCHEMBL6292471 | 0.82 | TMEM97 (0.60) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL10151525 | 0.81 | MAOA (0.51) | F10MAOAMAOBLMNAPTGS1 | |
| SCHEMBL7128269 | 0.81 | MAOA (0.42) | F10MAOAMAOBLMNAPTGS1 | |
| SCHEMBL7129096 | 0.81 | F10 (0.41) | F10MAOAMAOBLMNAPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030216374-A1 | Antibiotic oxazolidinone derivatives | SYNGENTA LIMITED (GB) | 2003-11-20 | — | — | US | disclosed |
| US-6605630-B1 | Active against drug resistant gram positive pathogens | SYNGENTA LIMITED (GB) | 2003-08-12 | — | — | US | disclosed |
| EP-1005468-A1 | ANTIBIOTIC OXAZOLIDINONE DERIVATIVES | ZENECA LIMITED (GB) | 2000-06-07 | — | — | EP | disclosed |
| WO-1999010342-A1 | ANTIBIOTIC OXAZOLIDINONE DERIVATIVES | ZENECA LIMITED (GB) | 1999-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216374-A1 | Antibiotic oxazolidinone derivatives | OXA1L, HRH1, OGDH | F10 795/4885MAOA 1078/4885MAOB 386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.